Search Results

Displaying Results 4001-4025 of 23036 "'K'"

Jul 27, 2026, 06:00 ET NHI Appoints Chris Maingot as Chief Operating Officer

not limited to, those risks and uncertainties which are described under the heading "Risk Factors" in Item 1A in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. Many of these factors are beyond the control of the Company and its management. The Company assumes no obligation

More news about: National Health Investors, Inc.


Jul 27, 2026, 06:00 ET IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA's filings with the Securities and Exchange Commission, including IDEAYA's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and current Reports on Form 8-K.Investor and Media ContactIDEAYA BiosciencesJoshua Bleharski, Ph.D.Chief

More news about: IDEAYA Biosciences, Inc.


Jul 27, 2026, 04:17 ET Comfytemp Expands Its Home Recovery Portfolio With Smart Cold Therapy System Designed to Make Post-Surgery Recovery More Accessible

technology, today announced the availability of its K91C1 Smart Cold Therapy System, a cold therapy solution designed to make post-operative recovery more comfortable and convenient for individuals

More news about: Comfytemp


Jul 26, 2026, 20:45 ET Synopsys Showcases Comprehensive Autonomous Engineering Workflows from Silicon to Systems, Developed with NVIDIA Technology

included in filings we make with the SEC from time to time, including in the sections entitled "Risk Factors" in our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Media ContactsKelli Wheeler, [email protected]

More news about: Synopsys, Inc.


Jul 26, 2026, 13:59 ET NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)

Aussagen enthaltenen abweichen, und die ausführlicher in den Abschnitten mit dem Titel „Risikofaktoren" im Jahresbericht des Unternehmens auf Formular 10-K, der am 18. Februar 2026 bei der Securities and Exchange Commission („SEC") eingereicht wurde, sowie in seinem Quartalsbericht auf Formular 10-Q, der

More news about: Menarini Industrie Farmaceutiche Riunite


Jul 25, 2026, 20:10 ET GPGI, CMPO Investors Have Opportunity to Lead GPGI, Inc. f/k/a CompoSecure, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of GPGI, Inc. f/k/a CompoSecure, Inc. (NYSE: GPGI, CMPO) between November 3, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important September 14, 2026 lead

More news about: THE ROSEN LAW FIRM, P. A.


Jul 25, 2026, 16:21 ET Rosen Law Firm Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation - PFSI

on the class action.What is this about: On January 29, 2026, PennyMac filed a Current Report with the Securities Exchange Commission on Form 8-K announcing PennyMac's fourth quarter and full-year 2025 financial results. The report stated that PennyMac's "servicing segment pretax income was $37.3 million,

More news about: THE ROSEN LAW FIRM, P. A.


Jul 25, 2026, 13:39 ET NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)

prospectives, qui sont décrits plus en détail dans les sections intitulées « Facteurs de risque » du rapport annuel de la Société sur le formulaire 10-K déposé auprès de la Securities and Exchange Commission (« SEC ») le 18 février 2026 et dans son rapport trimestriel sur le formulaire 10-Q déposé auprès

More news about: Menarini Industrie Farmaceutiche Riunite


Jul 25, 2026, 10:22 ET Chandigarh University's 272 Allied Health Sciences Students Secure Jobs in Prestigious Govt & Private Hospitals in Past 3 Years

SKIMS MCH Srinagar; CK Birla Hospital, Rajasthan; Government Medical College & Hospital, Chandigarh; and Government Medical College, Handwara (J&K). We also facilitated such internships for our foreign students at international institutions like Jigme Dorji Wangchuck National Referral Hospital,

More news about: Chandigarh University


Jul 25, 2026, 10:10 ET Rosen Law Firm Encourages Elauwit Connection, Inc. Investors to Inquire About Securities Class Action Investigation - ELWT

action.What is this about: On February 27, 2026, during market hours, Elauwit filed a Current Report with the Securities and Exchange Commission on Form 8-K announcing non-reliance on "previously issued interim financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended

More news about: THE ROSEN LAW FIRM, P. A.


Jul 24, 2026, 20:50 ET Dvaja absolventi Pekinskej univerzity získali Fieldsove medaily, 14 absolventov PKU prehovorilo na kongrese ICM 2026

tekutín, čím riešil problém, ktorý prvýkrát predostrel legendárny matematik David Hilbert pred viac ako storočím.Wangová a Deng sa prepracovali k matematike rôznymi spôsobmi, ale ich cesty sa začali v rovnakom ročníku na PKU. Ich úspechy poukazujú na rastúcu medzinárodnú prítomnosť matematikov z

More news about: Peking University


Jul 24, 2026, 20:33 ET Spoločnosť Shanghai Electric na veľtrhu WAIC 2026 predstavuje riešenia pre inteligentné továrne na báze AI

Podporujú plánovanie výrobnej linky, kontrolu kvality a prediktívnu údržbu, čím poháňajú vývoj výrobných systémov od operácií riadených skúsenosťami k operáciám riadeným dátami.Spoločnosť Shanghai Electric tiež vydala „Bielu knihu o technológii inteligentnej továrne s umelou inteligenciou", v

More news about: Shanghai Electric


Jul 24, 2026, 20:05 ET Portland General Electric declares dividend

factors identified from time-to-time in our filings with the United States Securities and Exchange Commission (SEC), including our annual report on Form 10-K for the year ended December 31, 2025 and subsequent quarterly reports on Form 10-Q. These reports are available through the EDGAR system free-of-charge

More news about: Portland General Company


Jul 24, 2026, 18:37 ET Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

to drive adoption at launch.VectorMist: On Track for FDA 510(k) SubmissionVectorMist, Vector's perioperative pain management technology for laparoscopic surgery, remains on track for submission to the FDA for 510(k) clearance, a process that typically involves a 90-day review from

More news about: Vector Sciences & Therapeutics


Jul 24, 2026, 17:06 ET ADTRAN Holdings Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ADTRAN Holdings (ADTN)

ADTRAN investors saw shares fall after a Form 8-K reported preliminary Q2 2026 results below guidance and tied the shortfall to a delayed single-customer project. The investigation focuses on whether ADTRAN adequately disclosed risks relating to customer project timing and impact on revenue and

More news about: Levi & Korsinsky, LLP


Jul 24, 2026, 16:05 ET Paramount Skydance Corporation Announces Extension of Expiration Dates of Previously Announced Exchange Offers and Tender Offers

other factors and the general risks associated with the respective businesses of Paramount and WBD can be found in Paramount's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 25, 2026, including in the sections captioned "Cautionary Note Concerning

More news about: Paramount Skydance Corporation


Jul 24, 2026, 16:00 ET METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR SECOND QUARTER 2026

in the sections titled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q on file with the U.S. Securities and Exchange Commission (the "SEC"), and in other documents that we file with the

More news about: MetroCity Bankshares, Inc.


Jul 24, 2026, 15:51 ET FSLR Deadline: FSLR Investors with Losses in Excess of $100K Have Opportunity to Lead First Solar, Inc. Securities Fraud Lawsuit

multimedia:https://www.prnewswire.com/news-releases/fslr-deadline-fslr-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-first-solar-inc-securities-fraud-lawsuit-302834357.htmlSOURCE

More news about: THE ROSEN LAW FIRM, P. A.


Jul 24, 2026, 15:24 ET Roblox Deadline: RBLX Investors with Losses in Excess of $100K Have Opportunity to Lead Roblox Corporation Securities Fraud Lawsuit

multimedia:https://www.prnewswire.com/news-releases/roblox-deadline-rblx-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-roblox-corporation-securities-fraud-lawsuit-302834377.htmlSOURCE

More news about: THE ROSEN LAW FIRM, P. A.


Jul 24, 2026, 14:00 ET FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)

uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent Quarterly Reports on Form 10-Q and other filings, available at

More news about: Kenvue Inc.


Jul 24, 2026, 13:43 ET cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

above and risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Actual results may differ materially. The company undertakes no obligation to update any forward-looking

More news about: cbdMD, Inc.


Jul 24, 2026, 13:11 ET FEDERAL HOME LOAN BANK OF BOSTON ANNOUNCES 2026 SECOND QUARTER RESULTS, DECLARES DIVIDEND

Item 5 — Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026 (the 2025 Annual Report).

More news about: Federal Home Loan Bank of Boston


Jul 24, 2026, 12:57 ET NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®

prospectivas, que se describen con mayor detalle en las secciones tituladas "Factores de riesgo" en el Informe anual de la Compañía en el Formulario 10-K presentado ante la Comisión de Bolsa y Valores ("SEC") el 18 de febrero de 2026 y en su Informe trimestral en el Formulario 10-Q presentado ante la SEC

More news about: Menarini Industrie Farmaceutiche Riunite


Jul 24, 2026, 10:45 ET INVESTOR DEADLINE: Intuit Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - INTU

least 8% revenue growth.  The Intuit class action lawsuit further alleges that on an accompanying conference call that day, Sasan K. Goodarzi, Intuit's Chairman and CEO, disclosed that TurboTax online paying units were expected to grow by only 2% as total Internal Revenue Service filers

More news about: Robbins Geller Rudman & Dowd LLP


Jul 24, 2026, 10:13 ET NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

the forward-looking statements, that are described in greater detail in the sections entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026,

More news about: Menarini Industrie Farmaceutiche Riunite


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.